

**Physical exertion at work and addictive behaviors: tobacco, cannabis, alcohol, sugar and fat consumption: longitudinal analyses in the CONSTANCES cohort**

Nadine Hamieh<sup>1,\*</sup>, Ph.D., Alexis Descatha<sup>2,3</sup>, M.D., Ph.D., Marie Zins<sup>4,5</sup>, M.D., Ph.D., Marcel Goldberg<sup>4,5</sup>, M.D., Ph.D., Sébastien Czernichow<sup>5,6</sup>, M.D., Ph.D., Marie Plessz<sup>7</sup>, Ph.D., Yves Roquelaure<sup>8,9</sup>, M.D., Ph.D., Cedric Lemogne<sup>5,10</sup>, M.D., Ph.D., Joane Matta<sup>4</sup>, Ph.D., Guillaume Airagnes<sup>1,4,5</sup>, M.D., Ph.D.

<sup>1</sup>AP-HP.Centre-Université de Paris, DMU Psychiatrie et Addictologie, Paris, France

<sup>2</sup>Poison Control Center, Academic Hospital CHU Angers, F-49000, Angers, France

<sup>3</sup>University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, INSERM, École des hautes études en santé publique, Institut de recherche en santé, environnement et travail UMR\_S 1085, F-49000 Angers, France

<sup>4</sup>INSERM, Population-based Epidemiological Cohorts Unit, UMS 011, Villejuif, France

<sup>5</sup>Université de Paris, Faculty of Health, School of Medicine, Paris, France

<sup>6</sup>AP-HP.Centre-Université de Paris, Hôpital européen Georges-Pompidou, Service de Nutrition, Paris, France

<sup>7</sup>INRAE, Centre Maurice Halbwachs (ENS, EHESP, CNRS) UMR 8097, Paris, France

<sup>8</sup>University of Angers, Centre Hospitalier Universitaire d'Angers, Université de Rennes, Centre de consultations de pathologie professionnelle et santé au travail, F-49000 Angers, France

<sup>9</sup>INSERM, EHESP, Irset - UMR\_S 1085, University of Angers, Université de Rennes, F-49000, Angers, France

<sup>10</sup>Université de Paris, AP-HP, Hôpital Hôtel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l'adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR\_S1266, Paris, France

\* Presenting author:

Nadine Hamieh, Ph.D.

AP-HP.Centre-Université de Paris

DMU Psychiatrie et Addictologie

20 rue Leblanc

75015 Paris, France

Email: [nadine.hamieh@inserm.fr](mailto:nadine.hamieh@inserm.fr)

Tel: +33 (0) 6 66 88 38 03

## **ABSTRACT**

**Objectives:** This study examined the prospective association of physical exertion at work with risk of tobacco, cannabis, alcohol use and sugar and fat consumption.

**Materials and methods:** Volunteers of the French population-based CONSTANCES cohort currently employed were included from 2012 to 2017 for tobacco and cannabis outcomes (n=100,612), and from 2012 to 2016 for alcohol and sugar and fat outcomes (n=75,414). High level of physical exertion was defined as a score  $\geq 12$  at the Rating Perceived Exertion Borg scale. Substance use was self-reported and patterns of sugar and fat intakes were obtained from principal component analysis and used in quartiles. Generalized linear models computed odds of substance use and sugar and fat consumption at follow-up according to baseline physical exertion at work, while adjusting for sociodemographic factors, depressive symptoms and baseline level of consumption.

**Results and conclusions:** High physical exertion was associated with tobacco use, i.e.: increased odd of relapse in former smokers (OR:1.13, 95% confidence Interval (CI):1.02-1.24), and increased number of cigarettes per day in current smokers (OR:1.54, 95%CI:1.33-1.78) with dose-dependent relationships ( $P$  for trend<0.001). It was also associated with increased odd of cannabis use at least once per month compared to no use in the past year (OR:1.31, 95%CI:1.03-1.66) and with increased odds of sugar and fat consumption (OR:1.06, 95%CI:1.01-1.11 and OR:1.13, 95%CI:1.07-1.18, for third and fourth quartiles compared to the first, respectively). As a conclusion, the associations between physical exertion at work and subsequent tobacco and cannabis use and sugar and fat consumption should be taken into account for information and prevention strategies.

## **TYPE OF PRESENTATION**

Oral presentation

## **CONFLICTS OF INTEREST**

Guillaume Airagnes declares personal fees from Lundbeck and Pfizer, outside the submitted work. Cédric Lemogne declares personal fees from Boehringer Ingelheim, Janssen-Cilag, Lundbeck and Otsuka Pharmaceutical, outside the submitted work. The other authors declare no conflicts of interest.